Coronary disease & ACSSecondary analysis
Intake of high-intensity statin after acute myocardial infarction assessed by direct drug concentration measurement: association with low-density lipoprotein cholesterol (LDL-C) response and coronary plaque modifications in the PACMAN-AMI trial
- Prespecified sub-study of the PACMAN-AMI randomised controlled trial
- pre-specified sub-study
Authors' conclusion
In the PACMAN-AMI trial, intake of high-intensity statin at 4 and 52 weeks post-AMI was excellent, with minimal statin intolerance.
Study context
- Population
- Patients with acute myocardial infarction (AMI) on protocol-mandated high-intensity statin (rosuvastatin or atorvastatin)255 with imaging and blood samples
- Participants
- 300 patients
- Comparison
- Adherent vs non-adherent to high-intensity statin
Primary result
As reported in the abstract
Non-adherence (no detectable statin) · 4 and 52 weeks
Non-adherent at 4 weeks
3 (1.2%)
Non-adherent at 52 weeks
5 (2.0%)
Reported statin intolerance within 52 weeks
four (1.3%)
Further findings
| Outcome | Adherent | Non-adherent |
|---|---|---|
| Changes in LDL-C and intracoronary imaging endpoints · 52 weeks · numerically greater reductions | ||
| LDL-C change | −2.73 mmol/L | +0.07 mmol/L |
| IVUS per cent atheroma volume change | −1.54% | −0.15% |
| NIRS maximum lipid core burden index change | −60.6 | 0.0 |
| OCT fibrous cap thickness change | +48.53 µm | +7.98 µm |
Sensitivity analysis excluding non-adherent patients
- Confirmed the robustness of the main study results
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Intake of high-intensity statin after acute myocardial infarction assessed by direct drug concentration measurement: association with LDL-C response and coronary plaque modifications in the PACMAN-AMI trial. Eur J Prev Cardiol. Published 12 August 2025. doi:10.1093/eurjpc/zwaf457
Summarised from the published abstract; every number is checked against it